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Regulatory T cells (Tregs) play a key homeostatic role by suppressing immune responses. 
They have been targeted in mouse and human cancer studies to improve vaccine 
immunogenicity and tumor clearance. A number of commercially available drugs and 
experimental vaccine adjuvants have been shown to target Tregs. Infants have high 
numbers of Tregs and often have poor responses to vaccination, yet the role Tregs play 
in controlling vaccine immunogenicity has not been explored in this age group. Herein, 
we explore the role of CD4+FOXP3+CD127− Tregs in controlling immunity in infant males 
and females to vaccination with diphtheria–tetanus–whole cell pertussis (DTP) and/or 
measles vaccine (MV). We find correlative evidence that circulating Tregs at the time of 
vaccination suppress antibody responses to MV but not DTP; and Tregs 4 weeks after 
DTP vaccination may suppress vaccine-specific cellular immunity. This opens the excit-
ing possibility that Tregs may provide a future target for improved vaccine responses in 
early life, including reducing the number of doses of vaccine required. Such an approach 
would need to be safe and the benefits outweigh the risks, thus further research in this 
area is required.
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inTrODUcTiOn
The human immune system has evolved multiple mechanisms to ensure the induction of protec-
tive immunity, whilst regulating damage from over exuberant or uncontrolled immune responses. 
Specialized T cell subsets known as regulatory T cells (Tregs) play a vital role in this process by 
restoring and maintaining a homeostatic environment following an inflammatory response to an 
immunogen (1).
Table 1 | Vaccines given from birth until 9 months of age in the three vaccine groups.
birth 8 weeks 12 weeks 16 weeks 9 months
MV group BCG, OPV, HepB DTP1, Hib, OPV, HepB DTP2, Hib, OPV DTP3, Hib, OPV, HepB MV
MV + DTP group BCG, OPV, HepB DTP1, Hib, OPV, HepB DTP2, Hib, OPV Hib, OPV, HepB MV + DTP3
DTP group BCG, OPV, HepB DTP1, Hib, OPV, HepB DTP2, Hib, OPV Hib, OPV, HepB DTP3
BCG, bacillus Calmette–Guérin vaccine; DTP1/2/3, diphtheria–tetanus–whole cell pertussis vaccine dose 1/2/3; HepB, hepatitis B vaccine; Hib, Haemophilus influenzae group b 
vaccine; MV, measles vaccine; OPV, oral polio vaccine.
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Regulatory T  cells were initially identified in mice as CD4+ 
T cells highly expressing CD25 (the alpha chain of the IL-2 recep-
tor) (2); but the later discovery of the forkhead family transcrip-
tion factor FOXP3 further defined Tregs, being central to their 
development and function (3, 4). Its importance is highlighted 
in Scurfy mice and humans with IPEX syndrome where FOXP3 
mutation results in uncontrolled inflammation and death (5). In 
humans, CD25 is also expressed by activated T cells (3), and it is 
the CD25hi subset that is suppressive (6). Low-level expression 
of CD127 (the IL-7 receptor) further defines functional Tregs 
in humans (7). Approximately 1–5% of human CD4+ T cells are 
CD4+FOXP3+ Tregs (4) and are either thymus derived natural 
Tregs or peripherally derived pTregs, which are indistinguishable. 
Tregs act by several modes of action including the induction of 
inhibitory cytokines, modulation of dendritic cell function, 
cytolysis, and metabolic disruption (8, 9).
Neonates and young children have highly adapted immune 
systems as compared to adults (10). Tregs in early life are highly 
suppressive, are present in higher frequencies than in adults, and 
are more naïve and less differentiated (11–14). The role of Tregs in 
controlling inflammation in infectious diseases remains contro-
versial, with studies reporting both beneficial effects of limiting 
immunopathology and detrimental effects with suppression of 
protective immunity allowing pathogen survival and persistence 
(15). Little is known about the role Tregs play in controlling 
vaccine immunogenicity in animals or humans (16). There is a 
need to determine whether circulating Tregs at the time of vac-
cination interfere with vaccine-induced responses, particularly in 
infants who suffer the greatest burden of infectious diseases, and 
where vaccine immunogenicity is often poor and Treg levels high. 
Understanding the homeostatic role of Tregs in infant vaccina-
tion may provide strategies to improve vaccine immunogenicity 
in this vulnerable age group.
We investigated for the first time whether preexisting cir-
culating CD4+FOXP3+CD127− Tregs influence antibody and 
cellular responses following vaccination with the live measles 
vaccine (MV) and killed diphtheria–tetanus–whole cell pertus-
sis (DTP) vaccine in 9-month-old Gambian infants, and further 
to determine whether Treg functional capacity is altered by 
vaccination.
MaTerials anD MeThODs
study Design
This study was nested into a larger randomized study investi-
gating the immunological effects of measles vaccination, DTP 
vaccination, or giving both vaccines together to 9-month-old 
Gambian infants, some of the results of which have been 
published previously (17). In this study, we focused on the role 
that Tregs play in regulating immune responses to these vac-
cines. 302 infants were recruited at 4 months of age at Sukuta 
Health Centre, a peri-urban area 20 km from the coast of The 
Gambia. Eligibility criteria included being well with no history 
of chronic illness, apyrexial (<37.5°C), normal weight-for-
age, and all recommended vaccines received to date. Infants 
were randomized into one of three vaccine groups (Table 1). 
At 4 months of age, Group 1 received DTP3 as normal while 
Groups 2 and 3 had their third dose of DTP withheld. All three 
groups received oral polio vaccine and Haemophilus influenzae 
b vaccine at 4 months of age. At 9 months of age, Group 1 were 
given MV alone; Group 2 received DTP3 with MV; and Group 
3 received DTP3 alone (Figure  1). Males and females were 
randomized separately.
ethics statement
The study protocol was approved by the Joint Gambia 
Government/MRC Ethics Committee (project number SCC1085) 
and the London School of Hygiene and Tropical Medicine Ethics 
Committee. Written informed consent was provided by a parent/
guardian of all participating infants.
blood sampling
Blood samples were taken at 9  months of age prior to vaccine 
administration, and 4 weeks later (10 months). Four and a half 
milliliters of venous blood was collected into heparin tubes and 
transported to the laboratory within 4 h of collection.
Ex Vivo Flow cytometric analysis for 
Tregs, T cell Memory, and Function
50 µL whole blood was stained with cocktails of fluorochrome-
conjugated surface antibodies to analyze for CD4 (CD4 APC-Cy7 
or PerCP) and CD8 (CD8 Pacific blue) T  cells expressing 
markers of Tregs (CD127 PE, FOXP3 APC); memory (CD45RO 
APC, CD62L PE-Cy7); terminal differentiation (CD57 FITC); 
activation (HLADR PerCP and CD38 PE-Cy7), proliferation 
(Ki67 FITC), and perforin production (Perforin PE) [Becton-
Dickinson (BD) for all fluorochromes except for CD8 PB, FOXP3 
APC, and CD62L PE-Cy7, which were from E-biosciences]. Red 
blood cells were lysed, and cells washed and incubated with 
surface antibodies for 30 min at 4°C. Cells for Treg analysis were 
then washed in 200 µL permeabilization buffer (E-biosciences); 
incubated with normal rat serum (1:50 dilution) for 15  min, 
4°C in the dark, then FOXP3 added and incubated for 30 min 
FigUre 1 | Study flowchart. 368 infants were assessed for eligibility and 302 (141 females and 161 males) randomized to one of the three vaccine groups; of whom 
286 received the vaccine intervention at 9 months of age; and 32 were lost to follow-up at 10 months of age. Blood samples were collected prior to vaccination at 
9 months and 4 weeks postvaccination at 10 months of age.
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at 4°C. Cells for Ki67 and perforin intracellular staining were 
washed with BD permeabilization buffer, Ki67 and perforin 
fluorochromes were added, and cells incubated for 30 min at 4°C 
in the dark. Stained cells were resuspended in 150 µL fix buffer 
(1% formalin in PBS), then acquired on the Cyan Flow cytometer 
(CyanADP). Flow cytometry data were analyzed using FlowJo 
software (Treestar, CA, USA) according to the gating strategies 
described (Figure 2).
Vaccine antibody Titers
The measles IgG hemagglutination inhibition assay (HAI) was 
performed using monkey red blood cells as described previ-
ously (18). Results are expressed as log2 units, the minimum 
detection level being 31.2  mIU, and a protective level defined 
as ≥125  mIU (log2 titer ≥3). A multiplex microsphere-based 
fluorescent immunoassay for IgG antibodies to diphtheria toxoid 
(Dtx), tetanus toxoid (Ttx), and four pertussis antigens [pertussis 
toxoid (Ptx), fimbriae, pertaxin, and filamentous hemagglutinin] 
was performed at the National Institute of Public Health and 
the Environment, Netherlands using published protocols (19). 
Protective levels for Dtx and Ttx are ≥0.1 IU/mL, but there is no 
established protective level for the pertussis antibodies.
beta-2 Microglobulin assay
The plasma beta-2 microglobulin (β2m) levels in milligrams per 
milliliter were measured by an automated microparticle enzyme 
immunoassay using an AxSYM automated machine (Abbott 
Laboratories, Wiesbaden, Germany) according to the manufac-
turer’s instructions.
Whole blood cultures
Heparinized whole blood was cultured in 100 µL aliquots in 96 
well U-bottom plates with tetanus toxoid (TT) (10 µg/mL, Sanofi 
Pasteur, France); a measles peptide pool of 122 15mer peptides 
overlapping by 10 amino acids spanning the measles protein 
hemagglutinin (all 1 µg/mL final concentration, Sigma-Genosys, 
UK); anti-CD3 (αCD3) (5 µg/mL, BD) plus anti-CD28 (αCD28) 
(5 µg/mL, E-biosciences) as a positive control T cell stimulus; and 
FigUre 2 | Flow cytometry gating strategy. Total lymphocytes were first gated on a forward scatter (FS)/side scatter (SS) plot (a) and then gated on the CD4+  
(b) or CD8+ population. These were then further gated for the subsets of interest, namely, CD4+FOXP3+CD127− regulatory T cells (c), HLADR+CD38+-activated 
CD4+ or CD8+ cells (D), Ki67+-proliferating CD4+ and CD8+ cells (e), and perforin+ CD8 T cells (F). The memory cells were first separated according to CD45RO 
expression (g) and then further phenotyped according to CD62L expression (h). Data were analyzed using FlowJo software, and population frequencies expressed 
as percent of the CD4 or CD8 parent population.
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medium alone as a background negative control. Antigen pulsed 
plates were incubated for 16 h at 37°C, 5% CO2, centrifuged and 
50 µL of supernatant collected and stored at −20°C for cytokine 
analysis.
Multiplex cytokine analysis
The Bio-Plex 200 Suspension Array system was used to analyze 
cytokines in plasma and culture supernatants (Bio-Rad, Belgium). 
The cytokines analyzed were interferon-gamma (IFN-γ), tumor 
necrosis factor (TNF), interleukin-1 beta (IL-1β), IL-4, and 
IL-10. Out of range values were assigned twice the upper limit of 
detection or half the lower limit of detection for those above and 
below range, respectively, as in previous studies (17). Medium 
background was subtracted from the antigen-stimulated value to 
establish antigen-specific cytokine production.
statistical analysis
Differences in Treg frequencies in vaccine groups at different 
time points were analyzed by two-sided Mann–Whitney U tests. 
Correlations were analyzed using Spearman’s rank correlation 
coefficient. p ≤ 0.05 was considered significant, and Bonferroni 
corrections for multiple testing were performed. Data were 
analyzed using GraphPad prism version 6.0 (GraphPad software, 
CA, USA).
resUlTs
no convincing effect of Vaccination on 
circulating cD4+FOXP3+cD127− Treg 
Frequencies
We first analyzed whether circulating Treg frequencies were 
altered following vaccination with MV, DTP, or both vaccines 
combined. When male and female donors were analyzed 
together, there was a significant decline in Tregs in the DTP-
vaccinated group (p =  0.039), but no change in the other two 
groups (Figure  3A). When males and females were analyzed 
separately, there was an increase in circulating Tregs in measles-
vaccinated females (p = 0.040) and a decrease in DTP-vaccinated 
males (p = 0.029) (Figure 3A). However, none of these changes 
remained significant after Bonferroni correcting for multiple 
testing and were therefore not considered convincing evidence of 
changes in Tregs postvaccination.
Vaccination affects immune activation 
and T cell Function
Beta-2 microglobulin levels increased after MV + DTP vac-
cination when all infants were analyzed together (p = 0.035), 
but not when analyzed by sex (Figure 3B). The frequency of 
CD38+HLADR+-activated CD4 T cells increased in the females 
FigUre 3 | Regulatory T cells (Tregs), plasma β2m, and activated CD4 and CD8 T cell levels before and after vaccination. Results for CD4+FOXP3+CD127− Treg 
frequencies (a), plasma β2m levels (b), activated CD4 T cells (c), and activated CD8 T cells (D) in the three vaccines groups at baseline (Pre) and 4 weeks after 
vaccination (post) for all infants combined, females and males separately. The bars show the median value in milligrams per liter; the error bars indicate the 95% 
confidence interval. Data were analyzed by Mann–Whitney U test, *p ≤ 0.05, **p ≤ 0.01, ^, no longer significant after correcting for multiple testing. Data are shown 
for Tregs: n = 194 infants, measles vaccine (MV) group n = 68 (31F, 37M), MV + DTP group n = 77 (43F, 34M), DTP n = 49 (26F, 23M); β2m: n = 259 infants, MV 
group n = 91 (39F, 52M), MV + DTP group n = 99 (47F, 52M), DTP n = 69 (33F, 36M); activated T cells: n = 158 infants, MV group n = 61 (28F, 33M), MV + DTP 
group n = 63 (32F, 31M), DTP n = 34 (19F, 15M).
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FigUre 4 | Proliferating and perforin producing T cell frequencies before and after vaccination. Results for CD4 T cell proliferation (a), CD8 T cell proliferation  
(b), and intracellular perforin levels (c) in the three vaccines groups at baseline (pre) and 4 weeks after vaccination (post) for all infants combined, females and males 
separately. The bars show the median value; the error bars indicate the 95% confidence interval. Data were analyzed by Mann–Whitney U test, *p ≤ 0.05, 
**p ≤ 0.01, ^, no longer significant after correcting for multiple testing. Data are shown for n = 158 infants, measles vaccine (MV) group n = 61 (28F, 33M), 
MV + DTP group n = 63 (32F, 31M), and DTP n = 34 (19F, 15M).
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who received MV + DTP simultaneously (p = 0.0073), but no 
other group (Figure  3C). By contrast CD38+HLADR+ CD8 
T  cells declined in infants following MV (p =  0.0403), but 
not the other vaccine groups (Figure 3D). CD4+ T cell pro-
liferation determined by Ki7 expression also increased in the 
MV + DTP group (all infants p = 0.0038; females p = 0.0017) 
(Figure  4A), while levels of proliferating CD4 and CD8 
T  cells declined in the DTP-vaccinated females (p =  0.0137 
and 0.0353, respectively), but not males (Figures 4A,B). After 
Bonferroni correction for multiple testing only the above 
changes in CD4 T cells proved to be statistically significant, 
namely, the altered activated and proliferating CD4 T  cells 
(Figures 3C and 4A).
CD8+ T cell perforin production increased in the MV + DTP 
group (all infants p = 0.008; males p = 0.0376) but declined in the 
DTP-vaccinated groups (all infants p = 0.0077; males p = 0.0224) 
(Figure  4C). After correcting for multiple testing, males and 
females combined had an increase in perforin+ CD8 T cells after 
MV + DTP and a decline after DTP alone.
None of the above effector readouts of proliferation, perforin 
production, or immune activation correlated negatively with 
circulating Tregs either at baseline or 4 weeks after vaccination.
7Ndure et al. Treg Role in Infant Vaccination
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altered Memory T cell Populations  
in Dual Vaccinated infants
We analyzed for effects on ex vivo circulating memory T  cell 
populations. It was striking that the only significant changes 
occurred in the group that received the MV and DTP vaccines at 
the same time, with no changes in the single vaccine groups. The 
CD4 naïve (CD4+CD45RO−CD62L+) population declined in the 
MV + DTP group for all infants (p < 0.0001), males (p < 0.0024), 
and females (p < 0.0001) (Figure 5A); while the T cell effector 
memory (TEM) (CD4+CD45RO+CD62L−) and CD45RA+ effec-
tors (TEMRA) (CD4+CD45RO−CD62L−) increased in this group 
(TEM: all infants p = 0.0001, females p = 0.0006, males p = 0.0337; 
TEMRA: all infants p < 0.0001, females p = 0.012, males p = 0.0009) 
(Figures  5B,C). The decreased CD4 naïve T  cell frequency in 
MV infants (p = 0.0292) was not significant after correcting for 
multiple testing (Figure 5A), nor was the TEM increase in males 
(Figure 5B). The CD8 population was less affected with only the 
naïve subset declining significantly in the MV + DTP group for all 
infants (p = 0.0038) and females (p = 0.0087) (Figure 5D). There 
was no change in central memory (TCM) (CD45RO+CD62L+) 
frequencies for CD4 or CD8 T cells for any vaccine group. The 
frequency of terminally differentiated T cells was examined by 
CD57 expression, hinting at a decline in MV + DTP-vaccinated 
infants for both CD4 and CD8 populations (p =  0.0455 and 
0.0464, respectively), although neither were significant after cor-
recting for multiple testing (not shown).
baseline cD4+FOXP3+cD127− Tregs 
negatively correlate with antibody 
responses to MV but not DTP
We previously showed that measles antibody titers 4 weeks after 
vaccination were not affected by simultaneous administration of 
DTP; nor were tetanus toxoid (Ttx), diphtheria toxoid (Dtx), and 
Ptx titers post-DTP vaccination altered by giving MV at the same 
time (17). To increase statistical power, we combined the MV and 
MV + DTP group to analyze for measles Ab correlations between 
baseline circulating Tregs and vaccine antibody levels 4 weeks later; 
and the DTP and MV + DTP groups to analyze for DTP Ab cor-
relations. This showed a significant negative correlation between 
baseline Tregs and measles Ab titers in infants who received MV 
(MV and MV + DTP groups combined) (r = −0.208, p = 0.048) 
(Figure 6A); but no correlation with any of the antibody readouts 
for DTP-vaccinated infants (Figures 6B–D). There were no sig-
nificant correlations between Tregs and vaccine antibodies when 
males and females were analyzed separately.
no correlations between baseline Tregs 
and Postvaccination cellular responses
We could not perform functional Treg assays in this study for 
logistic reasons including the multiple assays being conducted, 
small blood volumes, and lack of flow cytometry cell sorting 
facilities in The Gambia. We thus chose to analyze for correlations 
between CD4+FOXP3+CD127− Tregs and readouts of vaccine-
specific cellular immunity. We questioned whether baseline Tregs 
on the day of vaccination correlated negatively with subsequent 
vaccine-specific pro-inflammatory (IL-1β, TNF), Th1 (TNF, 
IFN-γ) or Th2 (IL-4) cellular responses 2 weeks after vaccination, 
or with the immunosuppressive cytokine IL-10, which can also be 
produced by activated Th1 and Th2 cells. There was no evidence 
for any significant correlation between baseline Tregs and subse-
quent cytokine responses to measles peptide or TT stimulation 
to suggest an immunoregulatory role for circulating Tregs at the 
time of vaccination.
Functionally suppressive Tregs Post-DTP 
Vaccination
We next analyzed for a correlation between the circulating Tregs 
4 weeks postvaccination and in vitro cytokine responses to the 
measles peptide pool, TT, PPD, and αCD3/αCD28 at the same 
time point. There was a negative correlation between postvaccina-
tion Tregs and the IFN-γ:IL-10 ratio in TT cultures (p = 0.0202, 
r = −0.471) and measles peptide cultures (p = 0.0475, r = −0.4001) 
in the DTP group only (Figures 7A,B). There was no correlation 
between postvaccination Tregs and cytokine responses to the 
T cell stimulus αCD3/αCD28 or the unrelated antigen PPD for 
any vaccine group to support an immunoregulatory role.
DiscUssiOn
Several studies suggest that FOXP3+ Tregs suppress the genera-
tion of immune responses to vaccination (16). The DEREG mouse 
model is a useful tool in this respect allowing Tregs depletion 
in vivo (20). Treg depletion using this model showed enhanced 
vaccine antitumor responses in a melanoma vaccine trial (21) and 
enhanced vaccine-induced solid tumor immune responses (22). 
In the latter study, Treg depletion was associated with enhanced 
CD8 activation and IFN-γ production, and increased NK cells. 
In mice, the administration of anti-CD25 mAbs to deplete Tregs 
enhanced CD4 and CD8 T cell responses to BCG and hepatitis 
B vaccines (23), and preexisting CD4+CD25+ Tregs suppressed 
BCG responses in vitro and in vivo (24).
Little is known about the role of Tregs in controlling human 
vaccine responses for any age group. Furthermore, translating 
the mouse into human studies may not be appropriate since their 
Tregs are phenotypically distinct. A human study showed marked 
increases in CD4+CD25hiFOXP3+ Tregs following vaccination 
with a DC-based HIV vaccine, and enhanced T cell immunity 
in vitro following Treg depletion (25). We have previously shown 
that infant BCG vaccination induces CD4+CD25+FOXP3+ 
Tregs, but they did not negatively correlate with IFN-γ reactiv-
ity to PPD to support a regulatory role (26). By contrast, the 
TB vaccine MVA85A was associated with a small decrease in 
CD4+CD25hiCD39+ Tregs (27) decreased TGF-β mRNA and 
serum levels up to 12 weeks after vaccination (28).
The changes in Treg frequencies after vaccination were not sig-
nificant after correcting for multiple testing, thus the question of 
whether MV or DTP vaccination alters Treg frequencies remains 
unresolved and further studies are needed. Tregs remained 
stable in the group that received MV + DTP; but this group had 
increased CD8 T  cell perforin production; and increased CD4 
T cell activation and proliferation among females but not males. 
FigUre 5 | Effect of vaccination on naïve and memory T cell frequencies. Results for CD4 naïve T cell frequencies (a), CD4 TEM (CD4+CD45RO+CD62L−) cells  
(b), CD4 TEMRA (CD4+CD45RO−CD62L−) cells (c), and CD8 naïve T cell frequencies (D) in the three vaccines groups at baseline (pre) and 4 weeks after vaccination 
(post) for all infants combined, females and males separately. The bars show the median value; the error bars indicate the 95% confidence interval. Data were 
analyzed by Mann–Whitney U test, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001, ^, no longer significant after correcting for multiple testing. Data are shown 
for n = 230 infants, measles vaccine (MV) group n = 83 (37F, 46M), MV + DTP group n = 91 (43F, 48M), and DTP n = 56 (27F, 29M).
8
Ndure et al. Treg Role in Infant Vaccination
Frontiers in Immunology | www.frontiersin.org August 2017 | Volume 8 | Article 921
FigUre 6 | Correlations between baseline circulating regulatory T cells (Tregs) at the time of vaccination and vaccine antibodies 4 weeks later. The frequency of 
Tregs at 9 months of age on the day of vaccination is shown on the x-axis, and the IgG antibody titers at 10 months are shown on the y-axis. (a) There was a 
significant inverse correlation between baseline Tregs and measles HAI titers for all measles-vaccinated infants [measles vaccine (MV) and MV + DTP groups 
combined]. Diphtheria toxoid (Dtx) titers (b), Ttx titers (c), and pertussis toxoid (Ptx) titers (D) for DTP vaccine recipients (DTP and MV + DTP groups) failed to 
correlate with baseline Tregs. The line indicates the best-fit correlation using Spearman’s rank correlation coefficient, and the correlation coefficient (r value) and  
p value for the correlation are shown. Data for 97 measles-vaccinated (47F, 50M) and 81 DTP-vaccinated (45F, 36M) infants are shown.
FigUre 7 | Correlation between regulatory T cells (Tregs) and vaccine-specific cytokine responses 4 weeks after vaccination. There was a significant inverse 
correlation between postvaccination Tregs and interferon-gamma (IFN-γ):IL-10 in TT culture supernatants at the same time point for DTP-vaccinated infants  
(a). There was also a significant inverse correlation for IFN-γ:IL-10 in measles peptide pool cultures in the DTP group (b). The line indicates the best-fit correlation 
using Spearman’s rank correlation coefficient, and the correlation coefficient (r value) and p value for the correlation are shown. Data for 25 DTP-vaccinated infants 
(18F, 7M) are shown.
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The MV + DTP group also experienced a decline in naïve CD4 
and CD8 T  cell frequencies, and increased CD4 TEM and CD4 
TEMRA populations following vaccination, with some sex differ-
ences in this effect. These results are consistent with our previous 
findings that combining MV with DTP vaccination has immune 
suppressing effects on PPD cellular responses and RNA expres-
sion in males, but the opposite effect in females, compared to 
giving DTP or MV alone (17).
Sex differences have been described for antibody and 
cellular responses to many vaccines, with females generally 
mounting higher responses, and also suffering greater adverse 
events (29–32). Females are also generally more susceptible 
to the non-targeted heterologous effects of vaccines, whereby 
vaccination alters the host’s response to subsequent exposure to 
unrelated (heterologous) organisms or vaccines (33, 34). Thus 
the sex differences described in this study are to be expected, 
but are often overlooked in immunological studies because 
they are not specifically analyzed for. Sex differences in Treg 
frequencies have not be described in infants although males 
have higher levels later in life (32), and we found no convincing 
evidence of a sex difference in our study either before or after 
vaccination.
In a small study, baseline regulatory cytokine gene expression 
(TGF-β and IL-10) at the time of vaccination with the malaria 
vaccines RTS,S/ASO2A and MVA-CS showed an inverse cor-
relation with subsequent antibody responses (35). Our results 
similarly suggest that Tregs at the time of vaccination suppress 
primary antibody responses to measles vaccination, but had no 
effect on secondary DTP vaccine antibody responses. We have 
since repeated this finding of a significant negative correlation 
between baseline Tregs and MV antibodies using a different 
Treg definition (CD4+CD25hiFOXP3+) and different time point 
(2  weeks post-measles vaccination) in a separate prospective 
cohort (in preparation). Potential mechanisms include direct 
suppression of B  cells via cell-contact mechanisms involving 
TGF-β and CTLA-4 (36); and suppression of T cell help essential 
for B  cell activation and expansion (37). If confirmed, Tregs 
could provide a functional target for enhancing vaccine antibody 
responses in infancy.
We analyzed for associations between Tregs and key CMI 
readouts as an indication of Treg function. We hypothesized that 
baseline Tregs at vaccination might suppress subsequent CMI 
to vaccination, and postvaccination Tregs might be functionally 
suppressive. We further speculated that the live and killed vac-
cines might have different effects in these respects. We found no 
evidence that baseline Tregs affected subsequent ex vivo plasma 
cytokines or β2m, activated or proliferating CD4 or CD8 T cells, 
CD8 T  cell perforin production, or measles and TT-specific 
cytokine responses.
The inverse correlation between the circulating 
CD4+FOXP3+CD127− Tregs post-DTP vaccination and the 
postvaccination IFN-γ:IL-10 ratio in TT and measles peptide 
cultures, but not PPD or αCD3/αCD28, may support a vaccine-
specific immunoregulatory role. No such correlations were 
observed in the MV or MV + DTP groups. However, given the 
multiple factors analyzed in these correlations these findings may 
well be type 1 error and further studies are required. If true, it 
would suggest that some vaccines, but not others, may induce 
suppressive Tregs. Indeed, we have found that mice immunized 
with aluminum adjuvant preferentially expand CD4+CD25+FOX
P3+TNFR2+ Tregs in draining lymph nodes, providing a potential 
mechanism whereby Tregs may be more functionally suppres-
sive following vaccination with the aluminum adjuvanted DTP 
vaccine (unpublished). We previously showed suppressed type 
1 immunity to αCD3/αCD28 stimulation in DTP-vaccinated 
females but not males in this cohort (17); but found no significant 
correlations between Tregs and αCD3/αCD28 cytokine responses 
to suggest Tregs were responsible for this.
There are several limitations to this study. We only had one 
postvaccination time point that does not reveal the dynamics of 
the immune factors analyzed. Power was reduced due to multiple 
comparisons, but corrections for multiple testing were done to 
allow for this. The Treg function conclusions are based on cor-
relations rather than functional suppressive assays, although 
many studies use this approach. Nevertheless the results offer 
potential insights into the immunoregulatory role that circulating 
CD4+FOXP3+CD127− Tregs, either at the time of vaccination or 
postvaccination, may play in controlling vaccine immunogenic-
ity in infants.
Certain vaccine adjuvants preferentially expand Teff over 
Tregs, e.g., the TLR3 agonist Poly(I:C) and the TLR9 agonist 
CpG-ODN; whereas others favor Treg expansion, e.g., the TLR7 
agonist imiquimod (38). Thus adjuvants might be selected for 
future infant vaccines that allow for optimal Teff responses. 
Chemokine receptor 4 (CCR4) antagonists have been used as 
vaccine adjuvants to target and decrease local recruitment of 
CCR4+ Tregs to amplify vaccine responses at the immunization 
site (39). The mAb to OX40, part of the TNFR superfamily, 
increases Teff function while blocking Treg function; and 
humanized OX40 clones have been generated which enhance 
the immunogenicity of vaccines against infectious diseases 
(40). There are also a number of therapeutic agents that can 
manipulate Tregs in vivo. For example, low dose cyclophospha-
mide transiently decreases Treg frequencies while preserving 
effector T  cell (Teff) function, permitting enhanced vaccine 
immunogenicity in mouse and human cancer vaccine trials 
(41, 42). Treg depletion with anti-CD25 monoclonal antibodies 
enhanced vaccine efficacy in mouse melanoma (43) and pan-
creatic carcinoma (44). The antihuman CD25 mAbs basiliximab 
and daclizumab decrease Treg number and function by blocking 
IL-2 signaling (45, 46); and daclizumab has been used to deplete 
Tregs and improve effector responses in human breast cancer 
vaccine trials (47, 48). The human mAb, ipilimumab, inhibits 
Tregs by blocking CTLA-4 and is FDA approved for use in 
melanoma patients (49).
While the above therapeutic approaches are not currently 
appropriate for infant vaccination strategies where any immune 
benefits will likely be outweighed by adverse effects, they dem-
onstrate the future potential for Treg manipulation to improve 
vaccine immunogenicity. Transient Treg depletion would be 
preferable, since prolonged depletion could lead to increased 
immune pathology and autoimmunity. By contrast, the adjuvant 
approaches discussed above are already available and could 
be used to improve vaccine immunogenicity in vulnerable 
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populations such as neonates and infants. To do this, we need 
to understand the role that Tregs play in controlling responses 
to early life vaccines. We hope our results will galvanize further 
research in this dynamic and evolving field.
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